ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/Pharmaceutical Intermediate/Semaglutide impurity 50
C24H46N4O13
598.6 g/mol
Pharmaceutical Intermediate

Semaglutide impurity 50

CAS2773558-66-8
Category
Pharmaceutical Intermediate
Compound Class
Peptide
Primary Use
Pharmaceutical Intermediate

Semaglutide impurity 50 is a linear, highly flexible polyethylene glycol-based compound containing multiple amide and ether linkages, used as a process impurity or intermediate in the manufacturing of semaglutide.

Pharmaceutical intermediate for semaglutide manufacturingReference standard for impurity profiling

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing Semaglutide impurity 50?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

StrongStructure SimilarSimilarity 1.00

2-[2-[2-[[2-[2-(2-aminoethoxy)ethoxy]acetyl]amino]ethoxy]ethoxy]acetic acid

CAS1143516-05-5

pharmaceutical intermediate

StrongStructure SimilarSimilarity 1.00

H-AEEA-AEEA-AEEA

CAS2773558-06-6

research compound

ReferenceSame Category

2,2,2-TRIFLUOROETHYL CHLOROFORMATE

CAS27746-99-2

pharmaceutical intermediate

ReferenceSame Category

6-methoxy-2-methyl-3,4-dihydro-2H-naphthalen-1-one

CAS27752-24-5

pharmaceutical intermediate

ReferenceSame Category

Deacetyl acebutolol

CAS27783-53-5

pharmaceutical intermediate

ReferenceSame Category

Ethyl (E)-hex-2-enoate

CAS27829-72-7

pharmaceutical intermediate

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more
Identifiers
IUPAC Name

2-[2-[2-[[2-[2-[2-[[2-[2-[2-[[2-[2-(2-aminoethoxy)ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetic acid

InChIKey

PCVLTPXWKGYYGD-UHFFFAOYSA-N

SMILES

C(COCCOCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)N

Synonyms (4)
  • H-AEEA-AEEA-AEEA-AEEA
  • Semaglutide impurity 50

Sourcing Semaglutide impurity 50?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→